Compare SPPL & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPPL | CLGN |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 23.1M |
| IPO Year | 2023 | N/A |
| Metric | SPPL | CLGN |
|---|---|---|
| Price | $4.60 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 4.1K | ★ 27.8K |
| Earning Date | 04-10-2026 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,591,508.00 | $2,475,000.00 |
| Revenue This Year | N/A | $1,617.28 |
| Revenue Next Year | N/A | $83.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.27 | ★ 280.77 |
| 52 Week Low | $2.18 | $1.30 |
| 52 Week High | $16.80 | $4.98 |
| Indicator | SPPL | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 34.38 |
| Support Level | $4.30 | $1.30 |
| Resistance Level | $5.36 | $1.93 |
| Average True Range (ATR) | 0.36 | 0.15 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 46.48 | 28.52 |
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.